.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Evolving Approaches in the Treatment of AML and MDS

Sponsored in part by Servier Pharmaceuticals. Content independently developed by OncLive.

EP. 1: Dr. Rivero on Monocytic Differentiation in AML

April 14th 2022

Gustavo Rivero, MD, discusses evolving therapies for patients with acute myeloid leukemia with monocytic differentiation.

EP. 2: Dr. Carraway on Next-Generation Sequencing in AML

April 14th 2022

Hetty Carraway, MD, discusses important considerations for the future of acute myeloid leukemia regarding mutations and next-generation sequencing.

EP. 3: Dr. Pollyea on the Role of Maintenance Therapy in AML

April 14th 2022

Dan Pollyea, MD, MS, discusses the current role of maintenance therapy in patients with acute myeloid leukemia who are unfit for intensive chemotherapy.

EP. 4: Genomics Guide Treatment, But Novel Agents Generate Excitement in AML and HR-MDS

April 28th 2022

New data ranging from up-front approaches with targeted therapy to maintenance therapy, as well as emerging findings with novel agents continue to push the paradigm forward in acute myeloid leukemia and higher-risk myelodysplastic syndromes.